News

Finch Therapeutics Announces Positive Topline Results from Randomized Controlled Trial of CP101, an Oral Microbiome Drug, for the Prevention of Recurrent C. difficile Infection

Finch Therapeutics & Takeda Expand Collaboration to Develop Microbiome Therapeutics Using Finch’s Human-First Discovery Platform

Finch Therapeutics Announces Appointment of Dr. Jo Viney and Domenic Ferrante to its Board of Directors

Finch Therapeutics Raises $53 Million to Advance Microbiome-Based Therapies for Recurrent C. Difficile, Autism and other Disease Areas

Finch Therapeutics Receives Fast Track Designation for the Investigation of Full-Spectrum Microbiota as a Treatment for Children with Autism Spectrum Disorder

Finch Therapeutics’ Investigational Drug CP101 Granted Breakthrough Therapy Designation from FDA for Recurrent C. Difficile Infection

Finch Therapeutics Expands Its Leading Microbiome IP Estate with Six New Patents

Finch Therapeutics Group Raises $36 Million in Series B Financing

Finch Therapeutics and Crestovo Announce Merger to Form Finch Therapeutics Group, a Leading, Fully Integrated Microbiome Company

Finch Therapeutics and Takeda Announce Global Collaboration to Develop Microbiome Therapeutics in Inflammatory Bowel Disease (IBD)